OC
DFTX

Oppenheimer & Co’s Definium Therapeutics DFTX Stock Holding History

Oppenheimer & Co’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-98,336
Closed -$638K – 1708
2025
Q2 		$638K Buy
98,336
+27,221
+38% +$179K 0.01% 1054
2025
Q1 		$416K Buy
71,115
+5,574
+9% +$39.9K 0.01% 1143
2024
Q4 		$456K Buy
65,541
+13,160
+25% +$90.5K 0.01% 1100
2024
Q3 		$298K Buy
+52,381
New +$364K ﹤0.01% 1232
2022
Q3 		– Sell
-854
Closed -$8K – 1430
2022
Q2 		$8K Sell
854
-1
-0.1% -$13 ﹤0.01% 1399
2022
Q1 		$14K Buy
+855
New +$14.8K ﹤0.01% 1459

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Oppenheimer & Co's DFTX Position: Q3 2025 in Review

Oppenheimer & Co sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 98,336 shares — an estimated $638K sold.

Oppenheimer & Co first reported a position in DFTX in Q1 2022 and held it in 6 quarters. The position peaked at $638K in Q2 2025. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • Oppenheimer & Co reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Oppenheimer & Co sold 98,336 Definium Therapeutics shares in Q3 2025, an estimated $638K.
  • Oppenheimer & Co first reported a position in Definium Therapeutics in Q1 2022 and held it in 6 quarters.
  • Oppenheimer & Co's Definium Therapeutics position peaked at $638K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Oppenheimer & Co's 13F filing for Q3 2025, filed 6 Nov 2025.